mRNA 1440

Drug Profile

mRNA 1440

Alternative Names: H10N8 Antigen mRNA; VAL 506440

Latest Information Update: 10 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Valera LLC
  • Class Anti-infectives; Antibodies; RNA; RNA vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus infections

Most Recent Events

  • 27 Apr 2017 Safety and immunogenicity data from a phase I trial in Influenza-A virus infections (In volunteers, Prevention) released by Moderna Therapeutics
  • 09 Jan 2017 Moderna Therapeutics completes enrolment in a phase I trial in Influenza A virus H10N8 subtype (Prevention, In volunteers) in Germany
  • 11 Jan 2016 Phase-I clinical trials in Influenza A virus H10N8 subtype (Prevention, In volunteers) in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top